Traders Buy Teva Pharmaceutical Industries (TEVA) on Weakness

Traders purchased shares of Teva Pharmaceutical Industries (NYSE:TEVA) on weakness during trading hours on Monday. $57.12 million flowed into the stock on the tick-up and $30.37 million flowed out of the stock on the tick-down, for a money net flow of $26.75 million into the stock. Of all stocks tracked, Teva Pharmaceutical Industries had the 11th highest net in-flow for the day. Teva Pharmaceutical Industries traded down ($0.14) for the day and closed at $21.09

A number of analysts have issued reports on the company. Cantor Fitzgerald set a $18.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Thursday, May 17th. Zacks Investment Research raised Teva Pharmaceutical Industries from a “sell” rating to a “hold” rating in a report on Wednesday, May 9th. Oppenheimer reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Monday, May 7th. Morgan Stanley reaffirmed a “hold” rating and issued a $18.00 target price on shares of Teva Pharmaceutical Industries in a report on Monday, May 7th. Finally, Credit Suisse Group set a $23.00 target price on Teva Pharmaceutical Industries and gave the company a “buy” rating in a report on Monday, May 14th. Ten research analysts have rated the stock with a sell rating, sixteen have given a hold rating and six have given a buy rating to the company. Teva Pharmaceutical Industries currently has an average rating of “Hold” and an average target price of $19.82.

The company has a debt-to-equity ratio of 1.80, a current ratio of 1.00 and a quick ratio of 0.65. The stock has a market capitalization of $21.45 billion, a P/E ratio of 5.40, a P/E/G ratio of 1.72 and a beta of 0.67.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, May 3rd. The company reported $0.91 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.28. The business had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.80 billion. Teva Pharmaceutical Industries had a positive return on equity of 18.59% and a negative net margin of 72.36%. Teva Pharmaceutical Industries’s revenue was down 10.0% on a year-over-year basis. During the same quarter last year, the company earned $1.06 EPS. equities analysts forecast that Teva Pharmaceutical Industries will post 2.45 earnings per share for the current year.

In other Teva Pharmaceutical Industries news, Director Roberto Mignone acquired 750,000 shares of the business’s stock in a transaction on Thursday, May 10th. The stock was purchased at an average price of $19.24 per share, for a total transaction of $14,430,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 5,684 shares of company stock valued at $105,411 in the last 90 days. 0.43% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. CIBC World Markets Inc. raised its position in Teva Pharmaceutical Industries by 184.1% in the 1st quarter. CIBC World Markets Inc. now owns 396,130 shares of the company’s stock valued at $6,770,000 after purchasing an additional 256,698 shares during the last quarter. Legal & General Group Plc raised its position in shares of Teva Pharmaceutical Industries by 14.6% during the first quarter. Legal & General Group Plc now owns 611,919 shares of the company’s stock worth $10,458,000 after acquiring an additional 77,766 shares during the last quarter. Cubist Systematic Strategies LLC raised its position in shares of Teva Pharmaceutical Industries by 139.1% during the first quarter. Cubist Systematic Strategies LLC now owns 31,487 shares of the company’s stock worth $538,000 after acquiring an additional 18,319 shares during the last quarter. Freestone Capital Holdings LLC raised its position in shares of Teva Pharmaceutical Industries by 114.2% during the first quarter. Freestone Capital Holdings LLC now owns 242,304 shares of the company’s stock worth $4,141,000 after acquiring an additional 129,176 shares during the last quarter. Finally, LPL Financial LLC raised its position in shares of Teva Pharmaceutical Industries by 9.8% during the first quarter. LPL Financial LLC now owns 169,319 shares of the company’s stock worth $2,894,000 after acquiring an additional 15,154 shares during the last quarter. Hedge funds and other institutional investors own 64.73% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply